These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. Lee JW; Pussegoda K; Rassekh SR; Monzon JG; Liu G; Hwang S; Bhavsar AP; Pritchard S; Ross CJ; Amstutz U; Carleton BC; Ther Drug Monit; 2016 Aug; 38(4):423-31. PubMed ID: 26960170 [TBL] [Abstract][Full Text] [Related]
63. Drug Approved to Prevent Cisplatin-Associated Ototoxicity in Children. Aschenbrenner DS Am J Nurs; 2023 Jan; 123(1):23. PubMed ID: 36546383 [TBL] [Abstract][Full Text] [Related]
65. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Ratain MJ; Cox NJ; Henderson TO Clin Pharmacol Ther; 2013 Dec; 94(6):631-5. PubMed ID: 24241639 [TBL] [Abstract][Full Text] [Related]
66. Ototoxicity prognostic models in adult and pediatric cancer patients: a rapid review. DeBacker JR; McMillan GP; Martchenke N; Lacey CM; Stuehm HR; Hungerford ME; Konrad-Martin D J Cancer Surviv; 2023 Feb; 17(1):82-100. PubMed ID: 36729346 [TBL] [Abstract][Full Text] [Related]
67. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Rybak LP Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):364-9. PubMed ID: 17823555 [TBL] [Abstract][Full Text] [Related]
68. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM; Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322 [TBL] [Abstract][Full Text] [Related]
69. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies. Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853 [TBL] [Abstract][Full Text] [Related]
72. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients. Waissbluth S; Del Valle Á; Chuang A; Becker A Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605 [TBL] [Abstract][Full Text] [Related]
73. Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity. Paken J; Govender CD; Pillay M; Ayele BT; Sewram V BMC Womens Health; 2021 Apr; 21(1):164. PubMed ID: 33879158 [TBL] [Abstract][Full Text] [Related]
74. GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs. Budai B; Prekopp P; Noszek L; Kovács ER; Szőnyi M; Erdélyi DJ; Bíró K; Géczi L J Mol Med (Berl); 2020 Jul; 98(7):963-971. PubMed ID: 32435918 [TBL] [Abstract][Full Text] [Related]
75. Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database. Tanoshima R; Khan A; Biala AK; Trueman JN; Drögemöller BI; Wright GEB; Hasbullah JS; Groeneweg GSS; Ross CJD; Carleton BC; J Clin Pharmacol; 2019 Mar; 59(3):356-363. PubMed ID: 30452777 [TBL] [Abstract][Full Text] [Related]
76. Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors. Okada H; Kitagawa K Cancer Med; 2023 Apr; 12(7):7904-7910. PubMed ID: 36567514 [TBL] [Abstract][Full Text] [Related]
77. Mechanisms of Aminoglycoside- and Cisplatin-Induced Ototoxicity. Steyger PS Am J Audiol; 2021 Oct; 30(3S):887-900. PubMed ID: 34415784 [TBL] [Abstract][Full Text] [Related]
78. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa. Paken J; Govender CD; Pillay M; Ayele BT; Sewram V BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863 [TBL] [Abstract][Full Text] [Related]
79. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218 [TBL] [Abstract][Full Text] [Related]
80. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis. Dillard LK; Lopez-Perez L; Martinez RX; Fullerton AM; Chadha S; McMahon CM Cancer Epidemiol; 2022 Aug; 79():102203. PubMed ID: 35724557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]